» Articles » PMID: 28848364

Determinants of Virological Failure Among Patients on Highly Active Antiretroviral Therapy in University of Gondar Referral Hospital, Northwest Ethiopia: a Case-control Study

Overview
Publisher Dove Medical Press
Date 2017 Aug 30
PMID 28848364
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Viral load monitoring is used as an important biomarker for diagnosing treatment failure in patients with HIV infection/AIDS. Ethiopia has started targeted viral load monitoring. However, factors leading to virological failure are not well understood and studied. Thus, the aim of this study was to identify the determinants of virological failure among HIV-infected patients on highly active antiretroviral therapy at the University of Gondar Referral Hospital, Northwest Ethiopia.

Methods: A case-control study was conducted from May to June 2015. Cases were subjects who had already experienced virological failure; controls were those without virological failure. Data were extracted from 153 cases and 153 controls through chart review. A multivariate logistic regression analysis was carried out to identify factors associated with virological failure, and variables with a -value <0.05 were considered statistically significant.

Results: In this study, higher odds of virological failure was observed among patients aged <35 years (adjusted odds ratio [AOR] =2.52, 95% CI: 1.33, 4.77), who had had CD4+ count <200 cells/mm (AOR=9.03, 95% CI: 4.40, 18.50), showed poor adherence to antiretroviral therapy (ART) (AOR=15.80, 95% CI: 6.90, 36.50), and had taken ART for longer durations of 25-47 months (AOR=3.00, 95% CI: 1.10, 8.40) and ≥48 months (AOR=6.70, 95% CI: 2.70, 16.60).

Conclusion: This study showed that patients aged <35 years and with recent low CD4 count, poor adherence to treatment, and longer exposure to ART were positively and significantly associated with virological treatment failure. Therefore, evidence-based intervention should be implemented to improve adherence to ART, which in turn helps to boost immunity (CD4) and suppresses viral replication and load. Moreover, attention should be given to younger patients who have had ART for longer periods.

Citing Articles

Epidemiological and virological characteristics of people living with HIV on antiretroviral treatment for more than 6 months in virological failure in Brazzaville, Republic of Congo.

Got F, Malonga G, Malanda-Kiminou J, Akolbout M, Loubano-Mvoumbi G, Ebourombi D Access Microbiol. 2024; 6(11).

PMID: 39697999 PMC: 11652753. DOI: 10.1099/acmi.0.000805.v3.


Virological failure and associated factors among patients receiving anti-retroviral therapy in Ethiopia: A systematic review and meta-analysis.

Aytenew T, Asferie W, Ejigu N, Birhane B, Tiruneh Y, Kassaw A BMJ Open. 2024; 14(11):e087569.

PMID: 39613423 PMC: 11605831. DOI: 10.1136/bmjopen-2024-087569.


Factors linked to virological failure in people on a dolutegravir-based regimen in Mamelodi.

Mmatsoku M, Ngcobo S S Afr J Infect Dis. 2024; 39(1):670.

PMID: 39507520 PMC: 11538423. DOI: 10.4102/sajid.v39i1.670.


Determinants of virologic failure among adult HIV patients on first line antiretroviral treatment in Oromia, Central Ethiopia: 2022 a case-control study.

Ayana W, Ayana Hordofa M, Dechasa Yadeta A AIDS Res Ther. 2024; 21(1):42.

PMID: 38915090 PMC: 11194960. DOI: 10.1186/s12981-024-00625-4.


Predictors of antiretroviral treatment failure to the first line therapy: a cross-sectional study among Iranian HIV-positive adults.

Hashempour A, Khodadad N, Ziaei R, Rezaei B, Ghasabi F, Falahi S BMC Infect Dis. 2024; 24(1):358.

PMID: 38549051 PMC: 10976689. DOI: 10.1186/s12879-024-09251-x.


References
1.
Rabkin J . HIV and depression: 2008 review and update. Curr HIV/AIDS Rep. 2008; 5(4):163-71. DOI: 10.1007/s11904-008-0025-1. View

2.
Zuo Z, Liang S, Sun X, Bussell S, Yan J, Kan W . Drug Resistance and Virological Failure among HIV-Infected Patients after a Decade of Antiretroviral Treatment Expansion in Eight Provinces of China. PLoS One. 2016; 11(12):e0166661. PMC: 5172524. DOI: 10.1371/journal.pone.0166661. View

3.
Parienti J, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B . Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004; 38(9):1311-6. DOI: 10.1086/383572. View

4.
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016; 17 Suppl 4:s2-s104. DOI: 10.1111/hiv.12426. View

5.
Vidal J, Song A, Matos M, Bartmann D, Anjos G, Miranda E . High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil. Braz J Infect Dis. 2013; 17(1):41-7. PMC: 9427411. DOI: 10.1016/j.bjid.2012.08.022. View